FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2141569270> ?p ?o ?g. }

• W2141569270 endingPage "4454" @default.
• W2141569270 startingPage "4447" @default.
• W2141569270 abstract "Therapy for advanced prostate cancer centers on suppressing systemic androgens and blocking activation of the androgen receptor (AR). Despite anorchid serum androgen levels, nearly all patients develop castration-resistant disease. We hypothesized that ongoing steroidogenesis within prostate tumors and the maintenance of intratumoral androgens may contribute to castration-resistant growth. Using mass spectrometry and quantitative reverse transcription-PCR, we evaluated androgen levels and transcripts encoding steroidogenic enzymes in benign prostate tissue, untreated primary prostate cancer, metastases from patients with castration-resistant prostate cancer, and xenografts derived from castration-resistant metastases. Testosterone levels within metastases from anorchid men [0.74 ng/g; 95% confidence interval (95% CI), 0.59-0.89] were significantly higher than levels within primary prostate cancers from untreated eugonadal men (0.23 ng/g; 95% CI, 0.03-0.44; P < 0.0001). Compared with primary prostate tumors, castration-resistant metastases displayed alterations in genes encoding steroidogenic enzymes, including up-regulated expression of FASN, CYP17A1, HSD3B1, HSD17B3, CYP19A1, and UGT2B17 and down-regulated expression of SRD5A2 (P < 0.001 for all). Prostate cancer xenografts derived from castration-resistant tumors maintained similar intratumoral androgen levels when passaged in castrate compared with eugonadal animals. Metastatic prostate cancers from anorchid men express transcripts encoding androgen-synthesizing enzymes and maintain intratumoral androgens at concentrations capable of activating AR target genes and maintaining tumor cell survival. We conclude that intracrine steroidogenesis may permit tumors to circumvent low levels of circulating androgens. Maximal therapeutic efficacy in the treatment of castration-resistant prostate cancer will require novel agents capable of inhibiting intracrine steroidogenic pathways within the prostate tumor microenvironment." @default.
• W2141569270 created "2016-06-24" @default.
• W2141569270 creator A5001591556 @default.
• W2141569270 creator A5034997866 @default.
• W2141569270 creator A5047770287 @default.
• W2141569270 creator A5057037633 @default.
• W2141569270 creator A5067800417 @default.
• W2141569270 creator A5071509387 @default.
• W2141569270 creator A5079709333 @default.
• W2141569270 creator A5089016512 @default.
• W2141569270 date "2008-06-01" @default.
• W2141569270 modified "2023-10-14" @default.
• W2141569270 title "Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth" @default.
• W2141569270 cites W1985143543 @default.
• W2141569270 cites W1988349823 @default.
• W2141569270 cites W1990518525 @default.
• W2141569270 cites W1993284512 @default.
• W2141569270 cites W2003955264 @default.
• W2141569270 cites W2005658600 @default.
• W2141569270 cites W2014303129 @default.
• W2141569270 cites W2014476883 @default.
• W2141569270 cites W2019544029 @default.
• W2141569270 cites W2022133687 @default.
• W2141569270 cites W2022635468 @default.
• W2141569270 cites W2027983482 @default.
• W2141569270 cites W2030439010 @default.
• W2141569270 cites W2040556993 @default.
• W2141569270 cites W2041880296 @default.
• W2141569270 cites W2047495973 @default.
• W2141569270 cites W2058378922 @default.
• W2141569270 cites W2074497307 @default.
• W2141569270 cites W2077301757 @default.
• W2141569270 cites W2081922333 @default.
• W2141569270 cites W2085944444 @default.
• W2141569270 cites W2090181953 @default.
• W2141569270 cites W2094047371 @default.
• W2141569270 cites W2098684944 @default.
• W2141569270 cites W2099944680 @default.
• W2141569270 cites W2112005084 @default.
• W2141569270 cites W2114185421 @default.
• W2141569270 cites W2115685614 @default.
• W2141569270 cites W2117296712 @default.
• W2141569270 cites W2117965089 @default.
• W2141569270 cites W2118055719 @default.
• W2141569270 cites W2119776733 @default.
• W2141569270 cites W2123728867 @default.
• W2141569270 cites W2127529986 @default.
• W2141569270 cites W2128803757 @default.
• W2141569270 cites W2137996608 @default.
• W2141569270 cites W2140855177 @default.
• W2141569270 cites W2154943599 @default.
• W2141569270 cites W2155279970 @default.
• W2141569270 cites W2164225778 @default.
• W2141569270 cites W2329037156 @default.
• W2141569270 cites W2525520624 @default.
• W2141569270 cites W3009079267 @default.
• W2141569270 cites W4235285434 @default.
• W2141569270 cites W4238598808 @default.
• W2141569270 doi "https://doi.org/10.1158/0008-5472.can-08-0249" @default.
• W2141569270 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2536685" @default.
• W2141569270 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18519708" @default.
• W2141569270 hasPublicationYear "2008" @default.
• W2141569270 type Work @default.
• W2141569270 sameAs 2141569270 @default.
• W2141569270 citedByCount "1258" @default.
• W2141569270 countsByYear W21415692702012 @default.
• W2141569270 countsByYear W21415692702013 @default.
• W2141569270 countsByYear W21415692702014 @default.
• W2141569270 countsByYear W21415692702015 @default.
• W2141569270 countsByYear W21415692702016 @default.
• W2141569270 countsByYear W21415692702017 @default.
• W2141569270 countsByYear W21415692702018 @default.
• W2141569270 countsByYear W21415692702019 @default.
• W2141569270 countsByYear W21415692702020 @default.
• W2141569270 countsByYear W21415692702021 @default.
• W2141569270 countsByYear W21415692702022 @default.
• W2141569270 countsByYear W21415692702023 @default.
• W2141569270 crossrefType "journal-article" @default.
• W2141569270 hasAuthorship W2141569270A5001591556 @default.
• W2141569270 hasAuthorship W2141569270A5034997866 @default.
• W2141569270 hasAuthorship W2141569270A5047770287 @default.
• W2141569270 hasAuthorship W2141569270A5057037633 @default.
• W2141569270 hasAuthorship W2141569270A5067800417 @default.
• W2141569270 hasAuthorship W2141569270A5071509387 @default.
• W2141569270 hasAuthorship W2141569270A5079709333 @default.
• W2141569270 hasAuthorship W2141569270A5089016512 @default.
• W2141569270 hasBestOaLocation W21415692701 @default.
• W2141569270 hasConcept C104317684 @default.
• W2141569270 hasConcept C121608353 @default.
• W2141569270 hasConcept C126322002 @default.
• W2141569270 hasConcept C134018914 @default.
• W2141569270 hasConcept C142716871 @default.
• W2141569270 hasConcept C143998085 @default.
• W2141569270 hasConcept C170493617 @default.
• W2141569270 hasConcept C2776235491 @default.
• W2141569270 hasConcept C2777899217 @default.
• W2141569270 hasConcept C2777911890 @default.
• W2141569270 hasConcept C2779256933 @default.

• next